Alembic Pharmaceuticals Faces Financial Challenges Amid Mixed Market Performance
Alembic Pharmaceuticals has recently experienced an evaluation adjustment due to changes in its financial metrics and market position. The company reported a decline in operating profit and profit after tax, while maintaining a strong debt servicing capability. It is currently trading at a discount relative to peers.
Alembic Pharmaceuticals has recently undergone an evaluation adjustment, reflecting changes in its underlying financial metrics and market position. The stock's technical indicators have shifted, with the technical trend moving from a mildly bullish stance to a sideways position. This adjustment comes amid a backdrop of mixed performance across various time frames, with the stock showing a return of 1.52% over the past year, while profits have experienced a decline of 7%.In terms of financial health, Alembic Pharmaceuticals reported a significant drop in operating profit, which has decreased at an annual rate of 7.30% over the last five years. The company's operating profit to interest ratio has reached a low of 11.09 times, and the profit after tax for the latest quarter stands at Rs 156.89 crore, reflecting a decline of 12%. Despite these challenges, Alembic maintains a strong ability to service its debt, evidenced by a low debt to EBITDA ratio of 0.67 times.
The stock is currently trading at a discount compared to its peers' average historical valuations, and it has a notable institutional holding of 20.37%, indicating a level of confidence from larger investors in the company's fundamentals.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
